Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Strata Critical Medical (SRTAW) over the last 5 years, with Q3 2025 value amounting to $10.4 million.

  • Strata Critical Medical's Treasury Shares rose 272.18% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 272.18%. This contributed to the annual value of $9.3 million for FY2024, which is 7654.26% up from last year.
  • Per Strata Critical Medical's latest filing, its Treasury Shares stood at $10.4 million for Q3 2025, which was up 272.18% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's Treasury Shares peaked at $11.5 million during Q1 2024, and registered a low of $1.5 million during Q3 2021.
  • Moreover, its 5-year median value for Treasury Shares was $7.5 million (2023), whereas its average is $6.9 million.
  • Per our database at Business Quant, Strata Critical Medical's Treasury Shares soared by 21458.03% in 2022 and then tumbled by 2955.35% in 2023.
  • Strata Critical Medical's Treasury Shares (Quarter) stood at $2.4 million in 2021, then surged by 214.58% to $7.5 million in 2022, then dropped by 29.55% to $5.3 million in 2023, then surged by 76.54% to $9.3 million in 2024, then grew by 11.86% to $10.4 million in 2025.
  • Its Treasury Shares stands at $10.4 million for Q3 2025, versus $10.8 million for Q2 2025 and $10.9 million for Q1 2025.